Ozempic® (semaglutide)

Ozempic® (semaglutide) is a once-weekly GLP-1 medicine used with diet and exercise to improve blood sugar (A1C) in adults with type 2 diabetes. It also reduces the risk of major cardiovascular events (CV death, heart attack, stroke) in adults with T2D and established cardiovascular disease.
In January 2025, the FDA added an indication to reduce the risk of kidney disease progression and CV death in adults with T2D and chronic kidney disease. Typical dosing starts at 0.25 mg weekly for 4 weeks, then 0.5 mg, with possible increases to 1 mg or 2 mg as directed. Take it on the same day each week, any time of day, with or without food.
Not a weight-loss drug—we position Ozempic strictly for type 2 diabetes care within a clinician-supervised program.Prescription-only with eligibility screening, injection training, and regular monitoring through our care team.Boxed Warning: risk of thyroid C-cell tumors; do not use if you or family have MTC or if you have MEN2.
Common side effects include nausea, vomiting, diarrhea, constipation, and decreased appetite.
Review the Prescribing Information and Medication Guide before starting therapy.

• Adults with type 2 diabetes who need better blood sugar (A1C) control alongside diet and exercise.
• Adults with type 2 diabetes and established cardiovascular disease seeking to lower the risk of heart attack, stroke, or CV death.
• Adults with type 2 diabetes and chronic kidney disease to reduce the risk of kidney disease progression and related outcomes (per 2025 FDA update).
• Not for individuals with type 1 diabetes or for use in children under 18.
• Not a weight-loss medicine; weight change may occur, but Ozempic is not approved for weight loss.
• Patients with a history of MTC or MEN2 should not use Ozempic (see boxed warning/safety info).

• Prefilled pen strengths (3 mL pens): 2 mg/3 mL, 4 mg/3 mL, and 8 mg/3 mL single-patient-use pens. These correspond to dose settings that deliver 0.25 mg, 0.5 mg, 1 mg, or 2 mg once weekly as prescribed.
• Starting dose (initiation): 0.25 mg once weekly for 4 weeks to help your body adjust.
• Standard escalation: Increase to 0.5 mg once weekly at week 5; if additional glycemic control is needed, may increase to 1 mg, and then to 2 mg (max), each step typically after ≥4 weeks on the previous dose, as directed by your clinician.
• When to take it: The same day each week, any time of day, with or without food. You can change the dose day if >48 hours have passed since the last dose. 
• Missed dose rule: Take it as soon as possible within 5 days of the missed dose; if >5 days have passed, skip and take the next dose on your regular day—do not double up. 
• Storage (patient-facing): Keep unused pens refrigerated (2–8 °C). After first use, a pen can be kept at room temp (15–30 °C) or refrigerated and must be discarded after 8 weeks/56 days, even if medicine remains.

• Clinically proven benefits: Lowers A1C in adults with type 2 diabetes and reduces major cardiovascular events (CV death, heart attack, stroke) in those with established CVD.
• New in 2025: Also indicated to reduce risk of kidney disease progression and CV death in adults with T2D and chronic kidney disease.
• How it works: A GLP-1 receptor agonist that boosts glucose-dependent insulin, lowers glucagon, and slows gastric emptying to improve glycemic control.
• Secondary effects: Central satiety signaling may reduce appetite, supporting adherence to diet and lifestyle changes in a supervised program. 

Regulatory status: India’s drug regulator CDSCO approved Ozempic (semaglutide) in late Sep 2025 for adults with type-2 diabetes; rollout is prescription-only and now underway.

• Boxed Warning (thyroid C-cell tumors): Do not use if you or a family member has MTC or if you have MEN2; report neck lump, hoarseness, trouble swallowing, or shortness of breath immediately.
• Pancreatitis risk: Stop Ozempic and contact your clinician for severe, persistent abdominal pain (with or without vomiting), which may radiate to the back. 
• Eye, sugar, and lows: Can worsen diabetic retinopathy—report vision changes; and may cause hypoglycemia, especially with insulin or sulfonylureas—monitor and adjust meds as advised.
• Kidney & gallbladder: Can lead to acute kidney injury (often with dehydration) and gallbladder problems; maintain fluids and seek care for reduced urination or right-upper-abdominal pain/fever/jaundice. 
• Common GI effects: Nausea, vomiting, diarrhea, constipation, abdominal pain are typical early on; dose escalation and supportive care can help. ‍
• Use in specific groups: Not established in <18 years; discontinue at least 2 months before a planned pregnancy; avoid if allergic to semaglutide or ingredients. Prescription-only with clinician oversight.

At Reverseall, we combine the power of Ozempic with:

‍

• A medically-led screening process (to assess eligibility, contraindications, metabolic baseline)
• Custom nutritional plans (that align with weight-loss + metabolic optimisation)
• Movement science & progressive training protocols (especially important given your movement-rehab background)
• Weekly coaching check-ins, tracking transformation, tutor behavioural change, ensure adherence, manage side‐effects
• Step-down/transition strategy: as patients improve, tapering/maintenance options, long-term lifestyle sustainability